Every 424B that Neuraxis, Inc. (NRXS) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow NRXS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full NRXS filings page.
Neuraxis, Inc. is registering for resale up to 1,923,194 shares of common stock held by existing security holders. This is a secondary offering: only the selling stockholders will receive proceeds from any sale, while Neuraxis will not receive any cash from these transactions.
The registered shares consist of 849,212 issued shares, 923,776 shares underlying RSUs, and 150,206 shares issued to directors. As of July 22, 2026, 12,477,309 shares of common stock were outstanding. The selling stockholders may sell shares over time through various methods, including market and negotiated transactions, and may be deemed underwriters depending on how they sell.
Neuraxis is a growth-stage medical technology company focused on neuromodulation therapies for gastrointestinal disorders, led by its proprietary IB-Stim PENFS device for pediatric and adult functional abdominal pain and its RED device for rectal neuromuscular evaluation. The company is listed on the NYSE American under the symbol NRXS, with a closing share price of $6.59 on August 3, 2026, and qualifies as an emerging growth company, with extensive risk factors incorporated by reference.
Neuraxis, Inc. amends its prospectus supplement to increase its at-the-market offering capacity to up to $11,500,000 of Common Stock to be sold from time to time through Craig-Hallum Capital Group LLC under an existing Sales Agreement.
The supplement states the company sold $5.8 million of securities under the Sales Agreement from August 29, 2025 through April 20, 2026. Preliminary unaudited results show cash and cash equivalents of approximately $7.1 million as of March 31, 2026, net sales of about $1.6 million for the three months ended March 31, 2026 (versus $0.9 million for the comparable prior-year period), preliminary gross profit of $1.4 million, and a preliminary operating loss of $1.7 million for that quarter. The filing discloses a public float of $66,876,930 based on 11,505,421 shares outstanding as of April 20, 2026.
NeurAxis, Inc. amended its at-the-market program to offer and sell shares of common stock with an aggregate offering price of up to $6,270,000 through Craig-Hallum, subject to General Instruction I.B.6 of Form S-3.
The company reports it has not sold any securities under the Sales Agreement from August 29, 2025 through October 23, 2025. On a preliminary unaudited basis, cash and cash equivalents were approximately $4.4 million as of September 30, 2025. For Q3 2025, preliminary net sales were approximately $0.8 million, gross profits approximately $0.7 million, and operating loss approximately $2.1 million. For the nine months ended September 30, 2025, preliminary net sales were approximately $2.6 million versus approximately $1.9 million for the prior-year period.
As of October 23, 2025, public float was approximately $33,817,486, based on 9,986,294 shares outstanding and a $3.82 share price, and the company has sold $4,999,998 of securities under I.B.6 in the prior 12 months.